CanSino Biologics

Category

CanSino Biologics’ Ad5-nCoV the First COVID-19 Vaccine to Phase II Clinical Trials

China’s CanSino Biologics recently disclosed that the company was advancing its SARS-CoV-2 vaccine to a Phase II clinical trial making this vaccine candidate lead contender in the global race for an approved vaccine product. This decision is “based on the preliminary...

Pin It on Pinterest